DSP and neoplasm: By using tumour samples from NSCLC patients and studying immune infiltration in four different compartments (tumour, macrophages, leukocytes, and non-immune stroma), researchers found that DSP could identify prognostic biomarkers predicting the response to checkpoint therapy.